AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.400
-0.280 (-5.98%)
At close: Oct 9, 2026, 4:00 PM EDT
4.480
+0.080 (1.82%)
After-hours: Oct 9, 2026, 7:30 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year. That makes AN2 Therapeutics the 38,133rd largest employer in the world and 5,465th in the United States.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,727,429
Market Cap
166.04M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 144 |
| Adagene | 128 |
| Precision BioSciences | 67 |
| PepGen | 57 |
| ALX Oncology Holdings | 48 |
| Compass Therapeutics | 39 |
| Cue Biopharma | 29 |
| Canton Strategic Holdings | 12 |
ANTX News
- 11 days ago - AN2 announces extension of funding for tuberculosis research collaboration - TheFly
- 11 days ago - AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK - Business Wire
- 23 days ago - AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - AN2 Therapeutics presents clinical data supporting development of Epetraborole - TheFly
- 5 weeks ago - AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - Business Wire
- 6 weeks ago - AN2 Therapeutics appoints Trenor as Chief Medical Officer - TheFly
- 6 weeks ago - AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer - Business Wire
- 1 month ago - AN2 Therapeutics reports Q2 EPS (18c), two estimates (24c) - TheFly